Login / Signup

Optimal designs for phase II/III drug development programs including methods for discounting of phase II results.

Stella PreusslerMarietta KirchnerHeiko GötteMeinhard Kieser
Published in: BMC medical research methodology (2020)
Individual drug development planning for a specific program is necessary to find the optimal design. The optimal choice of the design parameters for a specific drug development program at hand can be found by our user friendly R Shiny application and package (both assessable open-source via [1]).
Keyphrases
  • phase ii
  • clinical trial
  • open label
  • quality improvement
  • phase iii
  • placebo controlled
  • double blind
  • public health
  • decision making